ZIM
LXRX icon

Zacks Investment Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Zacks Investment Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,011
Closed -$65K – 593
2021
Q1 		$65K Buy
+11,011
New +$76.2K ﹤0.01% 491

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zacks Investment Management's LXRX Position: Q2 2021 in Review

Zacks Investment Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2021, closing a stake of 11,011 shares — an estimated $65K sold.

Zacks Investment Management first reported a position in LXRX in Q1 2021 and held it in 1 quarter. The position peaked at $65K in Q1 2021. 107 funds tracked by Wall St. Rank hold LXRX as of Q2 2021.

  • Zacks Investment Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Zacks Investment Management sold 11,011 Lexicon Pharmaceuticals shares in Q2 2021, an estimated $65K.
  • Zacks Investment Management first reported a position in Lexicon Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Zacks Investment Management's Lexicon Pharmaceuticals position peaked at $65K in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2021.

Based on Zacks Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.